CY1122769T1 - Αγωγη της περιφερικης νευροπαθειας των μικρων ινων - Google Patents

Αγωγη της περιφερικης νευροπαθειας των μικρων ινων

Info

Publication number
CY1122769T1
CY1122769T1 CY20191101135T CY191101135T CY1122769T1 CY 1122769 T1 CY1122769 T1 CY 1122769T1 CY 20191101135 T CY20191101135 T CY 20191101135T CY 191101135 T CY191101135 T CY 191101135T CY 1122769 T1 CY1122769 T1 CY 1122769T1
Authority
CY
Cyprus
Prior art keywords
treatment
small fiber
fiber neuropathy
peripheral small
neuropathy
Prior art date
Application number
CY20191101135T
Other languages
English (en)
Inventor
Valerie MORISSET
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of CY1122769T1 publication Critical patent/CY1122769T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Artificial Filaments (AREA)

Abstract

Η παρούσα εφεύρεση αφορά την αγωγή της περιφερικής νευροπάθειας των μικρών ινών που περιλαμβάνει χορήγηση σε ένα υποκείμενο που έχει την ανάγκη αυτής μιας θεραπευτικά αποτελεσματικής ποσότητας 5-(4-{[(2-φθοροφαινυλ)μεθυλ]οξυ}φαινυλ)-προλιναμιδίου ή ενός φαρμακευτικά αποδεκτού άλατος, επιδιαλυτώματος ή προφαρμάκου αυτού.
CY20191101135T 2014-10-03 2019-10-31 Αγωγη της περιφερικης νευροπαθειας των μικρων ινων CY1122769T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417499.9A GB201417499D0 (en) 2014-10-03 2014-10-03 Novel use
PCT/GB2015/052886 WO2016051195A1 (en) 2014-10-03 2015-10-02 Small fibre neuropathy treatment

Publications (1)

Publication Number Publication Date
CY1122769T1 true CY1122769T1 (el) 2021-05-05

Family

ID=51946796

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101135T CY1122769T1 (el) 2014-10-03 2019-10-31 Αγωγη της περιφερικης νευροπαθειας των μικρων ινων

Country Status (14)

Country Link
US (1) US20170290802A1 (el)
EP (1) EP3200784B1 (el)
CY (1) CY1122769T1 (el)
DK (1) DK3200784T3 (el)
ES (1) ES2750355T3 (el)
GB (1) GB201417499D0 (el)
HR (1) HRP20191480T1 (el)
HU (1) HUE045907T2 (el)
LT (1) LT3200784T (el)
PL (1) PL3200784T3 (el)
PT (1) PT3200784T (el)
RS (1) RS59621B1 (el)
SI (1) SI3200784T1 (el)
WO (1) WO2016051195A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042384A1 (en) * 2016-11-02 2018-05-11 Biogen Ma Inc. Novel dosage regimen

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
AU632494B2 (en) 1988-05-20 1993-01-07 F. Hoffmann-La Roche Ag Immobilized sequence-specific probes
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1993022456A1 (en) 1992-04-27 1993-11-11 Trustees Of Dartmouth College Detection of gene sequences in biological fluids
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CA2212836C (en) 1995-02-13 2003-08-12 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
EP0892791B1 (en) 1996-04-12 2003-03-05 G.D. Searle & Co. N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
DK0912518T3 (da) 1996-07-18 2003-12-08 Merck Frosst Canada Inc Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PL194557B1 (pl) 1997-09-05 2007-06-29 Glaxo Group Ltd Pochodna 2,3-diarylopirazolo[1,5-b]pirydazyny, jej wytwarzanie, kompozycja farmaceutyczna zawierająca pochodną i jej zastosowanie
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
DE69915519T2 (de) 1999-02-27 2005-02-03 Glaxo Group Ltd., Greenford Pyrazolopyridine
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
PL3200784T3 (pl) 2020-03-31
EP3200784B1 (en) 2019-07-31
RS59621B1 (sr) 2020-01-31
GB201417499D0 (en) 2014-11-19
SI3200784T1 (sl) 2020-03-31
HRP20191480T1 (hr) 2020-06-12
DK3200784T3 (da) 2019-08-12
ES2750355T3 (es) 2020-03-25
PT3200784T (pt) 2019-09-10
LT3200784T (lt) 2019-09-10
WO2016051195A1 (en) 2016-04-07
EP3200784A1 (en) 2017-08-09
HUE045907T2 (hu) 2020-02-28
US20170290802A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
CY1123487T1 (el) Διαμορφωτες του ρυθμιστη αγωγιμοτητας διαμεμβρανης κυστικης ινωσης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CY1120950T1 (el) Θεραπεια ινωσης
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201790630A1 (ru) Способы получения рибозидов
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
EA201791576A1 (ru) Ингибитор jak
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112015022197A2 (pt) tratamento de cataplexia
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
CY1121930T1 (el) Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
SV2017005381A (es) Compuestos de imidazopiridazina
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы